Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
Portfolio Pulse from Vandana Singh
Roche's Phase 2/3 SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy failed to show benefit over Merck's Keytruda in lung cancer patients. The study did not meet its primary endpoints of progression-free survival and overall survival. Roche plans to halt the study and evaluate changes to the ongoing tiragolumab program.

July 05, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy failed to meet primary endpoints in lung cancer patients, leading to the halting of the study.
The failure of the SKYSCRAPER-06 study to meet its primary endpoints is a significant setback for Roche, likely leading to negative investor sentiment and a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Merck's Keytruda outperformed Roche's tiragolumab plus Tecentriq and chemotherapy in the SKYSCRAPER-06 study, reinforcing its position as a leading treatment for lung cancer.
The failure of Roche's study reinforces the efficacy of Merck's Keytruda, likely leading to positive investor sentiment and a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80